Products
FDA grants ANDA approval to olopatadine hydrochloride for ocular allergy relief
Generic of Alcon’s Pataday Once Daily Relief is intended for use as an antihistamine to treat itchy eyes.
Products
FDA grants ANDA approval for brimonidine tartrate and timolol maleate 0.2%|0.5%
Generic of AbbVie’s Combigan is formulated to lower IOP in glaucoma and ocular hypertension (OHT) patients.
Products
FDA approves ANDA for generic ketorolac tromethamine ophthalmic solution 0.5%
Generic of Allergan’s ACULAR is indicated to treat post-op pain and inflammation plus allergic conjunctivitis.
Products
FDA approves ANDA for Lupin's allergic conjunctivitis eye drop
Generic equivalent to Bausch + Lomb’s Alrex offers a lower-cost alternative for patients.
Pipeline
FDA approves ANDA for Lupin's bromfenac ophthalmic solution 0.09%
Topical drug is the generic equivalent of Bausch + Lomb’s Bromday; intended to treat pain and inflammation following cataract surgery.
Products
FDA approves FDC Limited's pilocarpine HCl ophthalmic solution
ANDA approval for generic eye drop extends to three concentrations: 1%, 2%, and 4%.
Business
Ollin Biosciences debuts with next-gen ophthalmic pipeline
Biotech launches with $100 million financing and a lead program addressing wet AMD and DME via a higher potency VEGF/Ang2 bispecific antibody.
Research
Pivotal study showcases enVista Envy IOL's full range of vision
Data includes meeting all efficacy and safety outcomes, with the lens demonstrating statistical superiority in visual outcomes and a favorable dysphotopsia profile.
Products
Scope introduces OPTASE HYLO FORTE dry eye drops
Artificial tear is formulated with active glycerin for moderate-to-severe dry eye disease, offering extra moisture and a protective cushion for long-lasting relief.
Pipeline
FDA extends review period for EYLEA HD expanded labeling
Delay follows a recent site inspection; proposed expansion includes a new indication, updated dosings for current indications, and a pre-filled syringe version.
Pipeline
4DMT releases 60-week phase 2 analysis on wet AMD gene therapy
Reported at ASRS, data supports sustained vision gains and a 78% reduction in supplemental injections for 4D-150’s highest dose as company preps for phase 3 trial.
Business
Leadership watch: PolyActiva, B+L, and Wills Eye make strategic changes
Check out the latest leadership news from the eyecare space, including two new execs at PolyActiva and a retinal disorder treatment specialist taking the helm at Wills Eye.
Business
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions
Check out the latest leadership news from the eyecare space, including a new CEO at ViaLase and a leading optometrist joining myze.
Products
Heidelberg showcases fully digital surgical visualization platform
The SeeLuma features an ergonomically-friendly design, 3D technology, and a new intraoperative OCT module, among other add-ons, for surgeons.
Products
Haag-Streit launches METIS 900 surgical control center
Newest ophthalmic microscope system features coaxial red reflex, LED illumination, ergonomically-friendly controls, and a compact design.
Pipeline
Glaukos reports positive IOP-lowering clinical data on iDose platform
Latest update includes 36-month follow-up; phase 4 results on iDose TR with cataract surgery; and a new phase 2b/3 study on a next-gen implant.
Pipeline
Viridian reports positive phase 3 data on veligrotug for chronic TED
Latest THRIVE-2 study findings detail a favorable safety profile, shorter dosing regimen, and a promising diplopia response and resolution rate.
Products
Alcon unveils Total30 for Astigmatism expanded parameters
New additions to the first and only reusable monthly lens feature key technologies for optimal comfort and a 2.75D cylinder.
Events
AOA debriefs on optometric legislative and advocacy updates
Executive Director Jon Hymers provides a rundown on the latest wins, ongoing and new advocacy efforts, and a new clinician collective during Optometry’s Meeting.
Events